B cell cancer is any cancer that starts in B cells, a type of white blood cell responsible for producing antibodies that fight infections. When B cells grow out of control, they can form tumors in lymph nodes, bone marrow, blood, or other organs. The major types include various forms of lymphoma, chronic lymphocytic leukemia, and multiple myeloma, and they range from slow-growing cancers that may not need immediate treatment to aggressive diseases requiring urgent therapy.
What B Cells Normally Do
B cells are one of two main branches of your adaptive immune system (T cells are the other). Their primary job is to recognize foreign invaders, like bacteria and viruses, and transform into specialized cells called plasma cells that pump out antibodies. Those antibodies lock onto specific threats and flag them for destruction. B cells also help activate T cells by capturing pieces of an invader and presenting them for inspection.
This antibody-making process is central to understanding why B cells are so vulnerable to cancer. To produce antibodies that match millions of possible threats, B cells constantly rearrange and edit their own DNA. That genetic shuffling is normal and necessary, but it also creates opportunities for errors. The same molecular machinery that rearranges antibody genes can accidentally cause chromosomal breaks, translocations, and mutations that switch on cancer-promoting genes. In roughly 50% of diffuse large B cell lymphoma cases, for example, a key gene called BCL6 gets hijacked when its normal control sequences are swapped with promoters from other active genes.
Main Types of B Cell Cancer
B cell cancers are broadly grouped by how fast they grow, where they appear, and which stage of B cell development they arise from.
Diffuse Large B Cell Lymphoma (DLBCL)
DLBCL is the most common aggressive B cell lymphoma. It typically presents as a rapidly growing mass in a lymph node or sometimes in organs outside the lymphatic system, like the stomach or brain. Because it grows quickly, it usually needs treatment soon after diagnosis. The overall five-year survival rate is about 65%, but outcomes vary significantly by stage: 80% for disease confined to a single region, dropping to roughly 56% when it has spread widely.
Follicular Lymphoma
Follicular lymphoma is the most common slow-growing (indolent) B cell lymphoma. It often develops quietly over years, and some people are diagnosed only when a doctor notices enlarged lymph nodes during a routine exam. Lower-grade follicular lymphoma may not require immediate treatment, though it can transform into a more aggressive lymphoma like DLBCL over time. That transformation involves major changes in the cancer’s molecular behavior and often requires a shift in treatment strategy.
Chronic Lymphocytic Leukemia (CLL)
CLL is a slow-growing cancer that fills the blood and bone marrow with abnormal B cells. It is the most common leukemia in adults and frequently discovered through routine blood work before any symptoms appear. Many people with early-stage CLL are monitored for years before treatment becomes necessary.
Mantle Cell Lymphoma
Mantle cell lymphoma is less common but tends to behave aggressively. It arises from B cells in a specific zone of the lymph node called the mantle zone and is identified by a characteristic genetic marker involving the cyclin D1 protein.
Other B Cell Cancers
Multiple myeloma originates from plasma cells, the final stage of B cell development. Burkitt lymphoma, marginal zone lymphoma, and Hodgkin lymphoma (which arises from B cells in the germinal center of lymph nodes, despite historically being classified separately) round out the broader spectrum. The World Health Organization classifies these cancers hierarchically, starting from the broad category of “mature B cell neoplasm” and narrowing down to specific entities and subtypes.
Symptoms to Recognize
The most common first sign is a painless, swollen lymph node, often in the neck, armpit, or groin. But B cell cancers can also cause a set of whole-body symptoms known as “B symptoms,” which carry specific clinical definitions: unexplained fever above 100.4°F (38°C), drenching night sweats severe enough that you need to change your bedclothes, and unexplained weight loss of more than 10% of your body weight within six months.
Other symptoms people report include fatigue, itching, and pain in lymph nodes after drinking alcohol. These don’t formally count as B symptoms, but their reappearance after treatment can signal a recurrence. Some people, particularly those with CLL or indolent lymphomas, have no noticeable symptoms at all for years.
Risk Factors
For most B cell cancers, there is no single clear cause. A family history of lymphoma, particularly in a parent or sibling, increases risk. A weakened immune system raises vulnerability, whether from an autoimmune condition, organ transplant medications, or HIV. Certain viral infections, most notably Epstein-Barr virus, are linked to specific subtypes like Burkitt lymphoma and some cases of Hodgkin lymphoma. But many people diagnosed with a B cell cancer have no identifiable risk factor at all.
How B Cell Cancer Is Diagnosed
Diagnosis starts with a biopsy, usually of an enlarged lymph node. A pathologist examines the tissue under a microscope and runs additional tests to confirm the type. Flow cytometry is one of the most important tools: it passes individual cells through a laser beam and identifies surface proteins that reveal exactly what kind of cell is present. For B cell cancers, the key markers include CD19 and CD20 (which confirm the cells are B cells) along with additional markers like CD5, CD10, and CD38 that help distinguish one type of lymphoma from another.
Immunohistochemistry, which stains tissue samples to highlight specific proteins, provides further detail. For example, mantle cell lymphoma is confirmed by staining positive for cyclin D1 and SOX11. Together, these techniques allow pathologists to classify the cancer precisely, which directly determines treatment choices.
Imaging scans, typically PET-CT, and bone marrow biopsies help determine how far the cancer has spread. Staging ranges from Stage I (one lymph node region) through Stage IV (widespread involvement), and the stage at diagnosis significantly affects the treatment plan and expected outcome.
Treatment Options
The treatment that transformed B cell cancer care arrived over 20 years ago: a targeted antibody therapy that locks onto the CD20 protein found on the surface of most malignant B cells. This drug became a standard part of treatment for follicular lymphoma, DLBCL, CLL, and mantle cell lymphoma, and it is typically combined with chemotherapy. The combination significantly improved survival rates across all of these diseases compared to chemotherapy alone.
For aggressive lymphomas like DLBCL, the standard first-line approach pairs this targeted antibody with a multi-drug chemotherapy regimen. Treatment usually spans several months of infusion cycles. For indolent lymphomas, the same antibody can be used as ongoing maintenance therapy after initial treatment to keep the cancer in remission longer.
CAR-T Cell Therapy
For B cell lymphomas that come back after standard treatment or don’t respond to it, CAR-T cell therapy has become a major option. The process involves collecting your own T cells, genetically engineering them in a lab to recognize the CD19 protein on cancerous B cells, and then infusing them back into your body. These modified T cells then hunt down and destroy CD19-carrying cancer cells.
Multiple CAR-T products are now approved for relapsed or refractory B cell lymphomas, and they differ mainly in their internal engineering. Some use one type of signaling component to activate the T cells, while others use a different one, which can affect how long the modified cells persist in the body. When cancers evade CAR-T therapy by losing the CD19 target on their surface, newer approaches targeting CD22 have shown complete response rates of around 70% in early studies.
Outlook and Survival
Prognosis varies enormously depending on the specific type, stage, and biology of the cancer. For DLBCL, the most common aggressive form, the five-year relative survival rate across all stages is about 65%. Caught early at Stage I, that number rises to 80%. Even at Stage III, where the cancer has spread to both sides of the diaphragm, the five-year survival is still around 67%.
Indolent lymphomas like follicular lymphoma generally have higher survival rates, though they tend to be chronic conditions that may recur and require treatment more than once over a person’s lifetime. CLL, similarly, can often be managed for many years. The introduction of targeted therapies and, more recently, CAR-T cell therapy has meaningfully improved outcomes across the spectrum of B cell cancers, particularly for patients whose disease returns after initial treatment.